SARS-CoV-2 in pediatric cancer: a systematic review.
Sandy SchlageThomas LehrnbecherReinhard BernerArne SimonNicole ToepfnerPublished in: European journal of pediatrics (2022)
• Review results comprising over 1000 pediatric COVID-19 cancer patients confirm mild courses of SARS-CoV-2 infection in most patients but also show the attributable mortality is at least 10 times higher compared to reports on hospitalized children without comorbidities. • Review identifies that chemotherapy was continued despite SARS-CoV-2 positivity in 18% of patients with individual chemotherapy modification according to the clinical course of SARS-CoV-2 infection and existing comorbidities. On this basis, no severe COVID-19 complications were associated to the continuation of chemotherapy in several cohort studies and two case reports.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- young adults
- papillary thyroid
- prognostic factors
- case report
- genome wide
- cardiovascular events
- early onset
- emergency department
- patient reported outcomes
- childhood cancer
- cardiovascular disease
- squamous cell
- squamous cell carcinoma
- patient reported